439 related articles for article (PubMed ID: 16387509)
1. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
2. Implications of insulin-like growth factor-I for prostate cancer therapies.
Kojima S; Inahara M; Suzuki H; Ichikawa T; Furuya Y
Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
[TBL] [Abstract][Full Text] [Related]
3. Interaction of IGF signaling and the androgen receptor in prostate cancer progression.
Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR
J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715
[TBL] [Abstract][Full Text] [Related]
4. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
5. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
[TBL] [Abstract][Full Text] [Related]
7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
8. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58.
Viereck V; Siggelkow H; Pannem R; Braulke T; Scharf JG; Kübler B
J Cell Biochem; 2007 Sep; 102(1):28-40. PubMed ID: 17372931
[TBL] [Abstract][Full Text] [Related]
10. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
11. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
12. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
Surmacz E
Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D
Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor.
Sekine Y; Furuya Y; Nishii M; Koike H; Matsui H; Suzuki K
Biochem Biophys Res Commun; 2008 Jul; 372(2):356-61. PubMed ID: 18489904
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
[TBL] [Abstract][Full Text] [Related]
16. Novel insights into the implication of the IGF-1 network in prostate cancer.
Papatsoris AG; Karamouzis MV; Papavassiliou AG
Trends Mol Med; 2005 Feb; 11(2):52-5. PubMed ID: 15694866
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
19. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
20. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
Avnet S; Sciacca L; Salerno M; Gancitano G; Cassarino MF; Longhi A; Zakikhani M; Carboni JM; Gottardis M; Giunti A; Pollak M; Vigneri R; Baldini N
Cancer Res; 2009 Mar; 69(6):2443-52. PubMed ID: 19258511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
